46
The mechanisms whereby anti-cholinergics improve asthma outcomes, such as lung function, symptoms 47 and rate of exacerbation, can be numerous. The most obvious is by affecting the contraction of airway 48 smooth muscle (ASM). The acetylcholine released from the cholinergic nerves is the most important 49 bronchoconstrictor that sets the baseline degree of contractile activation of ASM in healthy individuals.
50
Although the degree of ASM's contractile activation can also be fine-tuned by a plethora of other 51 bronchoconstrictors and bronchodilators in asthma, blocking the ceaseless effect of acetylcholine on 52 ASM by anti-cholinergics reduces, at any given moment, the overall degree of contractile activation.
53
Since the relationships that exist between the degree of contractile activation, ASM force, ASM 54 shortening, airway narrowing, airflow resistance and respiratory resistance are not linear, small 55 decreases in the contractile activation of ASM can be greatly amplified and thus translate into important 56 benefits on patient's well-being. Plus, many inflammatory and remodeling features that are often found 57 in asthmatic lungs synergize with the contractile activation of ASM to increase respiratory resistance.
58
This review recalls that the proven effectiveness of anti-cholinergics in the treatment of asthma could be 59 merely attributed to a small reduction in the contractile activation of ASM. 
82
Given that the molecular pathogenesis of asthma is variable between patients, as well as complex and 
92
Although vagal activity has always been thought to be more important in chronic obstructive pulmonary 93 disease than in asthma, the anti-cholinergics are increasingly used to treat asthma today. (Canning 2006 ).
118
The non-neuronal cholinergic system may also contribute (Pieper 2012) . The LAMAs are thus expected 119 to reduce, at any given moment, the contractile activation of ASM that is attributed to cholinergic tone.
120
For that very reason, the therapeutic benefits of LAMAs may not be surprising after all. This is because 121 the contractile activation of ASM is at the very base of a chain of events that raises respiratory 122 resistance. This chain of events is described in the first part of this review. Importantly, this chain of 
132
The stress, which is exclusively defined herein as the force per cross-sectional area generated by ASM, 
147
Owing to the sigmoidal activation-stress curve described above, an additive effect of two 
257
Because radius at the denominator is raised to the fourth power, airflow resistance increases 258 dramatically during luminal narrowing. In fact, halving the radius increases airflow resistance by 16-fold.
259
When related to the cross-sectional area of the airway lumen, airflow resistance changes inversely 260 according to the square of changes in luminal area (Figure 1 .4).
262
As ventilation increases, the propensity for flow to transit from a laminar to a turbulent flow increases. 
316
The heterogeneity of airway caliber at baseline and provoked by bronchoconstriction are examples
317
showing that the behavior of the whole system is not merely the sum of its parts. Indeed, closure or 
